ZAI LAB LTD-ADR (ZLAB) Stock News

USA - Nasdaq - NASDAQ:ZLAB - US98887Q1040 - ADR

17.55 USD

-0.22 (-1.24%)

Last: 12/15/2025, 12:22:38 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ZLAB Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Zai Lab Limited

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

9 days ago - By: Zai Lab Limited

Zai Lab Announces Updates to China’s National Reimbursement Drug List

a month ago - By: Zai Lab Limited

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

3 months ago - By: Benzinga

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

3 months ago - By: Stocktwits - Mentions: AMGN

News Image

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug

2 months ago - By: Zai Lab Limited

Zai Lab Announces Participation in Investor Conferences in November and December 2025

2 months ago - By: Zai Lab Limited

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

2 months ago - By: Zai Lab Limited

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

2 months ago - By: Zai Lab Limited

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

3 months ago - By: Investor's Business Daily - Mentions: PFE NYT LLY ONC ...

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

3 months ago - By: Zai Lab Limited

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

4 months ago - By: Zai Lab Limited

Zai Lab Announces Participation in Investor Conferences in September 2025

4 months ago - By: Zai Lab Limited

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

4 months ago - By: Zai Lab Limited

Zai Lab Establishes Oncology Scientific Advisory Board

4 months ago - By: Zacks Investment Research

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

4 months ago - By: Zai Lab Limited

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

5 months ago - By: Yahoo Finance - Mentions: GS BAC 9688 AMGN

Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment

5 months ago - By: Zai Lab Limited

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

6 months ago - By: Zai Lab Limited

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

6 months ago - By: Yahoo Finance - Mentions: VRNA

Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis

6 months ago - By: Zai Lab Limited

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025